Nifty Pharma News and Updates

Name: Latest research reports of Cipla Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Load latest

Cipla Ltd.

02 Sep 2025

1513.00

0.65%

India, RoW biz to stay steady, US drug pipeline - the next trigger

Buy: Cipla Ltd.

Target

Sharekhan

Cipla has robust domestic and global product pipelines. US product pipeline to be healthy and will be key to driving growth from H2FY26E and contribute significantly from FY27E onwards.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Glenmark Pharmaceuticals Ltd.

02 Sep 2025

1959.20

0.33%

Growth momentum and margin stability expected from H2FY26E

Buy: Glenmark Pharmaceuticals Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

29 Aug 2025

3567.10

-1.00%

Strong domestic player, Acquisitions hold key to growth

Buy: Torrent Pharmaceuticals Ltd.

Target

Sharekhan

Company’s India portfolio clocked a 13% CAGR in the past 5 years; its momentum is expected to continue led by the chronic portfolio and recent acquisition of JB Chemicals.

Torrent Pharmaceuticals Ltd. is trading above its 200 day SMA of 3329.3

Divi's Laboratories Ltd.

29 Aug 2025

5710.00

0.36%

Steady performance amid near-term headwinds; structural levers intact

Accumulate: Divi's Laboratories Ltd.

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.

Number of FII/FPI investors increased from 922 to 990 in Jun 2025 qtr.

Cipla Ltd.

27 Aug 2025

1513.00

0.65%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Cipla Ltd. is trading above its 200 day SMA of 1495.7

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025

Dr. Reddy's Laboratories Ltd.

26 Aug 2025

1244.70

1.72%

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Business Standard

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr. Reddy's Laboratories Ltd. is trading at high day volume of 4.1M.

Dr Reddy's launches drug for treatment of chronic constipation

Business Line | 26 Aug 2025 1 more

Aurobindo Pharma Ltd.

26 Aug 2025

1086.00

0.19%

Aurobindo unit gets UK nod for biosimilar breast cancer drug Dazublys

Business Standard

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, has secured UK MHRA approval for its trastuzumab biosimilar Dazublys, used in HER2-positive breast and gastric cancer treatment

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Sun Pharmaceutical Industries Ltd.

26 Aug 2025

1636.20

2.63%

Sun Pharma shares slip 3% after BofA downgrade on premium valuations

Economic Times

Bank of America downgraded Sun Pharma stock to underperform' from neutral', citing risks to premium valuations and slower speciality execution. The brokerage cut its target price, flagging concerns over Ilumya's Medicare exposure, pricing pressures, and limited earnings visibility despite strong initial performance.

Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1627.2

Zydus Lifesciences Ltd.

25 Aug 2025

991.15

0.94%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.